Vopratelimab (Mouse IgG2a)
Based on 1 Customer Validation
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy.
For research use only. We do not sell to patients.
- Purity: 97.00%
- Molecular Weight:146.67 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG2a kappa
Human
Aducanumab (Mouse IGG2a) (0.25 mg/kg, i.p., 2 doses at 6 and 11 days) has significant anti-tumor activity with long-term protection in B16-SIY tumor mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female A/J mice (6-8 weeks old) were injected subcutaneously with Sa1/N cells (1 × 106 cells/mouse) to induce Sa1/N fibrosarcoma mice model[1].
-
Dosage:0.25-0.3 mg/kg
-
Administration:i.p., 4 doses (7, 10, 14 and 17 days) for 11 days after tumors reaching approximately 100 mm3.
-
Result:Had significant anti-tumor activity with 7 out of 10 mice showing complete tumor regression.
Induced systemic long-term immunity with re-challenge with Sa1/N tumors ~45 days after the last treatment in Tumor-free mice.
Decreased the percentage of intratumoral CD4+FoxP3+ Treg within CD3+ cells, but increased in the CD8: Treg and CD4 Teff: Treg ratios in the tumors.
-
Animal Model:Mice were injected subcutaneously with B16-SIY cells to induce B16-SIY tumor mice model[1].
-
Dosage:0.25 mg/kg
-
Administration:i.p., 6 and 11 days
-
Result:Induced no tumor growth and survived re-challenge with B16-SIY tumors 10 weeks.
Induced T cells proliferation in both peripheral blood and spleen and tetramer+ T cells proliferation in spleen as well as the frequency of activated memory CD8 T cells.
Induced Treg depletion and increased effector T cell to Treg ratios.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 146.67 kDa
-
Color Colorless to light yellow
-
SMILES
[Vopratelimab (Mouse IgG2a)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vopratelimab (Mouse IgG2a) Related Classifications
HY-P99382A Related Classifications
Powered by Bioz